ArticleTranslational cancer research2026
Association between the systemic immune-inflammation index and overall survival in patients with leukemia: a multicenter cohort study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The systemic immune-inflammation index (SII; platelet × neutrophil/lymphocyte) is a well-established prognostic marker in solid tumors, but its clinical significance in leukemia remains unclear, where peripheral blood cytopenias may primarily reflect bone marrow failure rather than conventional cancer-related inflammation. This study aimed to evaluate the association between pretreatment SII and overall survival (OS) in patients with leukemia and to assess its prognostic relevance in a multicenter cohort. Methods: We retrospectively analyzed 609 leukemia patients from a multicenter registry, split into training (n=427) and validation (n=182) cohorts. Baseline SII was calculated before therapy. A data-derived SII threshold was identified in the training cohort using maximally selected rank statistics. OS was assessed using Kaplan-Meier curves, Cox regression, and restricted cubic splines (RCS). A nomogram was constructed based on the multivariable Cox model and internally evaluated using bootstrap calibration for 1- and 3-year survival. Results: An SII cutoff of 173.56 significantly separated survival (log-rank P<0.001). After adjustment for the demographic, comorbidity, and treatment variables available in the registry, higher SII (≥173.56) remained associated with a lower hazard of death [hazard ratio (HR) =0.41; 95% confidence interval (CI): 0.31-0.55; P<0.001]. Spline analyses suggested a nonlinear inverse association between SII and mortality. The nomogram showed acceptable internal calibration in both cohorts. Conclusions: Higher baseline SII was consistently associated with better OS in this multicenter leukemia cohort. This association may reflect differences in underlying disease burden and preserved hematopoietic function, rather than an independent biological effect of SII. Because leukemia subtype, disease status, and cytogenetic and molecular risk were unavailable, whether SII adds prognostic value beyond established leukemia risk factors remains uncertain. These findings support further evaluation of SII in well-characterized, subtype-specific cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.